Abstract:Background: The ability to detect tumor-specific biomarkers in real-time using optical imaging plays a critical role in preclinical studies aimed at evaluating drug safety and treatment response. In this study, we engineered an imaging platform capable of targeting different tumor biomarkers using a multi-colored library of nanoprobes. These probes contain rare-earth elements that emit light in the short-wave infrared (SWIR) wavelength region (900-1700 nm), which exhibits reduced absorption and scattering compared to visible and NIR, and are rendered biocompatible by encapsulation in human serum albumin. The spectrally distinct emissions of the holmium (Ho), erbium (Er), and thulium (Tm) cations that constitute the cores of these nanoprobes make them attractive candidates for optical molecular imaging of multiple disease biomarkers. Methods: SWIR-emitting rare-earth-doped albumin nanocomposites (ReANCs) were synthesized using controlled coacervation, with visible light-emitting fluorophores additionally incorporated during the crosslinking phase for validation purposes. Specifically, HoANCs, ErANCs, and TmANCs were co-labeled with rhodamine-B, FITC, and Alexa Fluor 647 dyes respectively. These Rh-HoANCs, FITC-ErANCs, and 647-TmANCs were further conjugated with the targeting ligands daidzein, AMD3100, and folic acid respectively. Binding specificities of each nanoprobe to distinct cellular subsets were established by in vitro uptake studies. Quantitative whole-body SWIR imaging of subcutaneous tumor bearing mice was used to validate the in vivo targeting ability of these nanoprobes. Results: Each of the three ligand-functionalized nanoprobes showed significantly higher uptake in the targeted cell line compared to untargeted probes. Increased accumulation of tumor-specific nanoprobes was also measured relative to untargeted probes in subcutaneous tumor models of breast (4175 and MCF-7) and ovarian cancer (SKOV3). Preferential accumulation of tumor-specific nanoprobes was also observed in tumors overexpressing targeted biomarkers in mice bearing molecularly-distinct bilateral subcutaneous tumors, as evidenced by significantly higher signal intensities on SWIR imaging. Conclusions: The results from this study show that tumors can be detected in vivo using a set of targeted multispectral SWIR-emitting nanoprobes. Significantly, these nanoprobes enabled imaging of biomarkers in mice bearing bilateral tumors with distinct molecular phenotypes. The findings from this study provide a foundation for optical molecular imaging of heterogeneous tumors and for studying the response of these complex lesions to targeted therapy.

A Cross-Talk EGFR/VEGFR-targeted Bispecific Nanoprobe for Magnetic Resonance/near-Infrared Fluorescence Imaging of Colorectal Cancer

Targeted Biodegradable Near-Infrared Fluorescent Nanoparticles for Colorectal Cancer Imaging

Novel Dual-Function Near-Infrared II Fluorescence and PET Probe for Tumor Delineation and Image-Guided Surgery.

An "imaging-biopsy" strategy for colorectal tumor reconfirmation by multipurpose paramagnetic quantum dots

A Tumor-Targeting and Polarity-Specific Near-Infrared Fluorescent Probe for Accurate Cancer Diagnosis in Vivo

Radiolabeled AIE Probes As Dual-modality Imaging Agents for PET/NIR-II Fluorescence-Guided Photothermal Therapy

Preclinical Evaluation of a Novel EGFR&c-Met Bispecific Near Infrared Probe for Visualization of Esophageal Cancer and Metastatic Lymph Nodes.

Targeting Upconversion Nanoprobes for Magnetic Resonance Imaging of Early Colon Cancer

Improving Sensitivity of Magnetic Resonance Imaging by Using a Dual-Targeted Magnetic Iron Oxide Nanoprobe.

Evaluation of the tumor-targeting specific imaging and killing effect of a CEA-targeting nanoparticle in colorectal cancer

A NIR-II Fluorescent Probe for High Contrast Non-Invasive Imaging of Tumors with a High EGFR-expression

Detection of early primary colorectal cancer with upconversion luminescent NP-based molecular probes

An inorganic magnetic fluorescent nanoprobe with favorable biocompatibility for dual-modality bioimaging and drug delivery.

Multimodality PET and Near-Infrared Fluorescence Intraoperative Imaging of CEA-Positive Colorectal Cancer

A Near-Infrared Fluorescent Probe With Assembly/Aggregation-Induced Retention Effect for Specific Diagnosis of Metastasis and Image-Guided Surgery in Breast Cancer

PET/NIR Fluorescence Bimodal Imaging for Targeted Tumor Detection

Shortwave infrared emitting multicolored nanoprobes for biomarker-specific cancer imaging in vivo

Excitation-Selectable Nanoprobe for Tumor Fluorescence Imaging and Near-Infrared Thermal Therapy.

Imaging of Colorectal Cancers Using Activatable Nanoprobes with Second Near‐Infrared Window Emission

Albumin-Based Cyanine Crizotinib Conjugate Nanoparticles for NIR-II Imaging-Guided Synergistic Chemophototherapy

EGFR-specific Single-Chain Variable Fragment Antibody-Conjugated Fe3O4/Au Nanoparticles As an Active MRI Contrast Agent for NSCLC